leadf
logo-loader
viewNaturally Splendid Enterprises Ltd.

Naturally Splendid says Health Canada approved Phase 2 clinical trial of Cavaltinib to treat COVID-19

The clinical trial design protocol, which calls for looking at the drug’s efficacy over a 30-day period, was submitted to the agency through a proposed joint venture with Biologic Pharmamedical Research

Naturally Splendid Enterprises Ltd. - Naturally Splendid says Health Canada approved Phase 2 clinical trial of Cavaltinib to treat COVID-19
Cavaltinib is licensed to another JV owned by Naturally Splendid and Biologic Pharmamedical

Naturally Splendid Enterprises Ltd (CVE:NSP) (OTCMKTS:NSPDF) announced Wednesday that Health Canada has approved a Phase 2 clinical trial of Cavaltinib to treat the COVID-19 disease caused by SARS-CoV-2 coronavirus. 

The clinical trial design protocol, which will look at the drug’s efficacy over a 30-day period, was submitted through a proposed joint venture with Biologic Pharmamedical Research. Cavaltinib already is licensed to another JV owned by Naturally Splendid and Biologic Pharmamedical based on technology and patents developed by Biologic.

"We are optimistic that Cavaltinib can be a major part of a successful treatment plan for COVID-19 positive patients,” said Franco Cavaleri, CEO and chief scientist at Biologic Pharmamedical, in a statement.

READ: Naturally Splendid Enterprises updates on clinical trial application for Cavaltinib to treat coronavirus

“With this treatment option for those who are at high risk of morbidity or mortality we may be able to provide hope while reducing the impact on Health Care Services and thus providing additional time for the scientific community to develop the right vaccines,” Cavaleri added. 

The drug has been shown to inhibit small proteins released by cells called cytokines that are central to the “cytokine storm” phenomenon, where the body starts to attack its own cells rather than just fighting off the virus as seen in critically ill COVID-19 patients.

"Cytokine storms are a common complication not only of COVID-19 but of other respiratory diseases caused by coronaviruses such as SARS and MERS,” Cavaleri said.“In fact, this mechanism of disease development is also similarly central to autoimmune and autoinflammatory diseases."

New JV called Plasm Pharmamedical Inc

Meanwhile, Naturally Splendid said the agreement for the second JV with Biologic Pharmamedical for the COVID-19 clinical trial to be called Plasm Pharmamedical Inc (PLASM) is being finalized and expected shortly. 

Biologic will license certain aspects of the patent comprising of the corresponding trademark Cavaltinib to PLASM. The categories to be licensed will include, but not be limited to COVID-19 applications, as well as respiratory indications that may come out of the fast-tracked clinical trial.

Naturally Splendid said it will invest $500,000 into the PLASM JV for the purpose of supporting the Phase 2 trial as well as research identifying additional indications of treatment. It will own 16% of the joint venture and receive a 10% royalty on the gross sales of all product sales by the JV.

“We are optimistic that Cavaltinib can be a viable treatment,” said Naturally Splendid VP of Operations Bryan Carson.

“However, we must also not lose sight of the fact that respiratory disease overall is on the rise as our environment evolves and infectious diseases become more pervasive. Although our immediate focus remains a treatment for COVID-19, the applied science that we stand to learn from these trials may have even far more reaching implications in regards to treatment for respiratory disease than our initial goal to mitigate the health implications of COVID-19".

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

 

 

Quick facts: Naturally Splendid Enterprises Ltd.

Price: 0.06 CAD

TSX-V:NSP
Market: TSX-V
Market Cap: $11.06 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Naturally Splendid Enterprises Ltd. named herein, including the promotion by the Company of Naturally Splendid Enterprises Ltd. in any Content...

FOR OUR FULL DISCLAIMER CLICK HERE

Naturally Splendid passes audit to maintain its Safe Quality Food Level 2...

Naturally Splendid (CVE: NSP-OTC: NSPDF) CEO Craig Goodwin joined Steve Darling from Proactive Vancouver to discuss the company once again passing their annual audit that certifies their Pitt Meadows, BC operation as a Safe Quality Food Level 2 certified food manufacturing facility. Goodwin...

on 8/7/20

3 min read